Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180355 | 0.88 | CYP2C19 (0.54) | CYP2C19ALDH1A1LMNAPOLBPKM | |
| E388 SCHEMBL11363669 | 0.86 | KMT2A (0.64) | CYP2C19ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL1477938 | 0.84 | ALDH1A1 (0.54) | CYP2C19ALDH1A1LMNAPOLBPKM | |
| SCHEMBL13870215 | 0.84 | FFAR1 (0.56) | CYP2C19ALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL44801 | 0.82 | CYP2C19 (1.00) | CYP2C19ALDH1A1LMNASMN1; SMN2HPGD | |
| SCHEMBL20111381 | 0.82 | CYP2C19 (0.66) | CYP2C19ALDH1A1LMNAPKMSMN1; SMN2 | |
| SCHEMBL23232300 | 0.81 | CYP2C19 (0.70) | CYP2C19ALDH1A1LMNAKMT2AHTT | |
| SCHEMBL20393450 | 0.81 | CYP2C19 (0.70) | CYP2C19ALDH1A1LMNASMN1; SMN2HPGD | |
| SCHEMBL8332405 | 0.81 | HTT (0.61) | CYP2C19ALDH1A1LMNAPOLBHPGD | |
| SCHEMBL8003157 | 0.81 | CYP2C19 (0.64) | CYP2C19ALDH1A1PKMSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0029659-A2 | Vasopressin analogs, processes for their production and a method of treating mammals | Cort, Joseph H. (US) | 1981-06-03 | — | — | EP | claimed |
| US-20130041000-A1 | NOVEL AZOLE COMPOUND | AJINOMOTO CO., INC. (JP) | 2013-02-14 | — | — | US | disclosed |
| US-7517996-B2 | Azole compound | AJINOMOTO CO., INC. (JP) | 2009-04-14 | — | — | US | disclosed |
| EP-1218098-A1 | MATRICES OF PROBES AND THEIR PREPARATION | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017670-A1 | MATRICES OF PROBES AND THEIR PREPARATION | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 2001-03-15 | — | — | WO | disclosed |
| US-5376635-A | A polypeptides as diuretics, hypotensive agents | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-12-27 | — | — | US | disclosed |
| EP-0283956-B1 | FLUORINE CONTAINING ATRIAL NATRIURETIC PEPTIDES | BIO-MEGA INC. (CA) | 1992-11-11 | — | — | EP | disclosed |
| US-4829051-A | CONTROLLING BLEEDING | VEGA LABORATORIES, INC. (US) | 1989-05-09 | — | — | US | disclosed |
| EP-0283956-A2 | Fluorine containing atrial natriuretic peptides | BIO-MEGA INC. (CA) | 1988-09-28 | — | — | EP | disclosed |
| US-4285858-A | ANTIHEMOPHILIC FACTOR; HEMOSTATIC AGENTS; ANTICOAGULANTS AND COAGULANTS | MT. SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF N.Y. (US) | 1981-08-25 | — | — | US | disclosed |
| EP-0029659-A2 | Vasopressin analogs, processes for their production and a method of treating mammals | Cort, Joseph H. (US) | 1981-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041000-A1 | NOVEL AZOLE COMPOUND | LPAR1, LPAR2, LPAR3 | CYP2C19 536/4885ALDH1A1 1467/4885LMNA 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.